Bioventus, Inc. (BVS)
| Market Cap | 850.18M |
| Revenue (ttm) | 376.09M |
| Net Income (ttm) | n/a |
| Shares Out | 41.81M |
| EPS (ttm) | -0.26 |
| PE Ratio | n/a |
| Forward PE | 10.04 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 314,364 |
| Open | 14.41 |
| Previous Close | 14.41 |
| Day's Range | 14.28 - 15.33 |
| 52-Week Range | 10.74 - 19.94 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Est. Earnings Date | Nov 9, 2021 |
About BVS
Bioventus Inc. a medical device company, focuses on developing and commercializing clinically treatments that engage and enhance the body's natural healing process in the United States and internationally. The company provides osteoarthritic joint pain treatment and joint preservation products, including Durolane, a single injection therapy; GELSYN-3, a three injection therapy; and SUPARTZ FX, a five injection therapy. It also offers bone graft substitutes comprising allograft-derived bone graft with growth factors, demineralized bone matrix, c...
Financial Performance
In 2020, Bioventus's revenue was $321.16 million, a decrease of -5.58% compared to the previous year's $340.14 million. Earnings were $16.41 million, an increase of 139.54%.
Financial StatementsNews
BIOVENTUS INC. and MISONIX, INC.
DURHAM, N.C. and FARMINGDALE, N.Y., Oct. 18, 2021 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) and Misonix, Inc. (Nasdaq: MSON) (“Misonix”), today announced an election deadline of 5:00 p.m., New Yo...
DUROLANE® Among High-Molecular Weight Hyaluronic Acid Treatments Linked to Significant Improvements in Knee Osteoarth...
DURHAM, N.C., Sept. 20, 2021 (GLOBE NEWSWIRE) -- Bioventus Inc., (Nasdaq: BVS) (“Bioventus” or the “Company”), a leader in innovations for active healing, announced that the American Academy of Orthopae...
Bioventus Proceeds with Option Structure Agreement with CartiHeal
DURHAM, N.C., Aug. 30, 2021 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, has elected to make a $50 million escrow p...
Bioventus Invests in Trice Medical Minimally Invasive Technologies
Bioventus Also Agrees to OUS Distribution and Co-Development Relationships Bioventus Also Agrees to OUS Distribution and Co-Development Relationships
Dave Crawford Joins Bioventus as Vice President, Investor Relations and Treasurer
DURHAM, N.C., Aug. 23, 2021 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, has appointed Dave Crawford as its Vice Pr...
SV Health Investors Announces Three Realizations in its Growth Equity Portfolio
BOSTON, Aug. 19, 2021 /PRNewswire/ -- SV Health Investors ("SV"), a leading global health care investment firm, is pleased to announce a series of realizations from its growth equity portfolio: On Augus...
Will a Powerful Acquisition Make This Early 2021 IPO a Buy?
Maybe the equivalent of an extra full quarter of revenue will get the attention of investors.
SHAREHOLDER ALERT: WeissLaw LLP Investigates Misonix, Inc.
NEW YORK, July 30, 2021 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Misonix, Inc. ("Misonix" or the "Compan...
Bioventus Scoops Up Misonix In $518M Stock & Cash Deal; Raises FY21 Sales Outlook
Recently listed Bioventus Inc (NASDAQ: BVS) has agreed to acquire Misonix Inc (NASDAQ: MSON) for $518 million in a cash-and-stock transaction. Misonix stockholders may elect to receive either 1.6839 Bio...
Bioventus and Misonix Announce Definitive Agreement for Bioventus to Acquire Misonix
The Combination Further Differentiates Bioventus' Product Portfolio and Accelerates Its Revenue Growth The Combination Further Differentiates Bioventus' Product Portfolio and Accelerates Its Revenue Growth
Bioventus Inc. Reports Preliminary Second Quarter Net Sales; Updates Full-Year 2021 Net Sales Guidance
DURHAM, N.C., July 29, 2021 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) ("Bioventus" or "the Company"), a global leader in innovations for active healing, today reported preliminary financial resul...
Bioventus® Management to Present at Canaccord Genuity Growth Conference and Morgan Stanley Virtual Global Healthcare ...
DURHAM, N.C., July 27, 2021 (GLOBE NEWSWIRE) -- Senior management of Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, will present at the C...
Bioventus Appoints Mary Kay Ladone to Board of Directors
DURHAM, N.C., July 14, 2021 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, has announced the appointment of Mary Kay ...
Bioventus Launches OSTEOAMP® SELECT Flowable Nationwide
DURHAM, N.C., July 13, 2021 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, is launching OSTEOAMP SELECT Flowable, a f...
Bioventus Invests in Vaporox
Ultrasonic Technology to Heal Diabetic Foot Ulcers Ultrasonic Technology to Heal Diabetic Foot Ulcers
Bioventus to Release Second Quarter of Fiscal Year 2021 Financial Results on August 10, 2021
DURHAM, N.C., June 16, 2021 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, today announced that second quarter of fis...
Will Bioventus (BVS) Continue to Surge Higher?
As of late, it has definitely been a great time to be an investor of Bioventus (BVS).
Bioventus Senior Management to Present at Upcoming Investor Conferences
DURHAM, N.C., May 17, 2021 (GLOBE NEWSWIRE) -- Senior management of Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, will present at the Ca...
Bioventus Inc. Reports First Quarter Results; Updates Full Year 2021 Financial Guidance
DURHAM, N.C., May 12, 2021 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) ("Bioventus" or "the Company"), a global leader in innovations for active healing, today reported financial results for three ...
Bioventus Announces First Commercial Shipment of the Bioness® Integrated Therapy System (BITS) Balance System
Fourteen Facilities Across the US Receive Multidisciplinary Therapy Solution Fourteen Facilities Across the US Receive Multidisciplinary Therapy Solution
Bioventus to Release First Quarter of Fiscal Year 2021 Financial Results on May 12, 2021
DURHAM, N.C., April 12, 2021 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, today announced that first quarter of fis...
Bioventus Acquires Bioness, Inc.
DURHAM, N.C., March 30, 2021 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, has acquired Bioness, Inc. (“Bioness”), a...
Bioventus Inc. Reports Fourth Quarter and Full Year 2020 Financial Results; Introduces Full Year 2021 Financial Guidance
DURHAM, N.C., March 25, 2021 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, today reported financial results for the ...
Bioventus Reports First Patients Enrolled in Phase 1 Clinical Trial of MOTYS™ (PTP-001) for the Treatment of Knee OA
DURHAM, N.C., March 11, 2021 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a leader in solutions for innovative healing, reported that the first patients have been enr...